HOME >> BIOLOGY >> NEWS
Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury

Hawthorne, NY June 28, 2002 Acorda Therapeutics announced today that it has begun two Phase 3 clinical studies of its lead product, Fampridine-SR, in chronic spinal cord injury. The trials will evaluate the safety and efficacy of Fampridine-SR in the treatment of moderate-to-severe spasticity associated with chronic SCI. Spasticity, which affects up to 75% of people with chronic SCI, manifests itself as involuntary stiffness or contraction of muscles.

The studies will enroll a total of 360 patients at more than 70 of the leading spinal cord injury (SCI) clinical centers in the United States and Canada. Individuals who are interested in finding out about participating in these studies may call 866-206-2322, toll-free, weekdays from 9:00 a.m. (EDT) to 7:00p.m. (EDT)

"There is significant demand for new treatment options in chronic spinal cord injury, especially spasticity. Spasticity is a serious complication of SCI that frequently interferes with movement and daily activities, and can cause severe pain or injury," said Ron Cohen, MD, Acorda's President and Chief Executive Officer.

Fampridine ("4-aminopyridine", "4-AP") enhances conduction in damaged nerves, and is the first compound shown to restore some neurological function to people with SCI. Fampridine-SR is an oral, sustained-release formulation of fampridine, designed for twice-daily dosing. The drug restores nerve conduction by blocking exposed potassium channels in demyelinated nerve processes, or axons. Fampridine-SR is also in Phase 2 clinical trials to evaluate safety and efficacy in the treatment of symptoms associated with multiple sclerosis (MS).

In previous SCI clinical trials, administration of Fampridine-SR has been shown to reduce spasticity, and to improve sexual function and bowel and bladder control. The most common side effects observed with Fampridine-SR treatment have been pain, paresthesia, insomnia, dizziness, constipation, and nausea. At clin
'"/>


1-Jul-2002


Page: 1 2

Related biology news :

1. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
2. Acorda Therapeutics acquires CeNeS neuregulin products
3. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
4. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
5. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
7. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
8. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
9. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. Immerge BioTherapeutics announces identification of PERV receptor

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... Va. (PRWEB) , ... November 13, 2019 , ... ... today that Robert Peterson, RAC , a regulatory affairs and program management ... the biopharmaceutical and medical device industries, has joined the firm as an Expert ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... of orthopedic medical devices, today announced the creation of a Global Regulatory Affairs ... the Medical Device industry is that the regulatory element to any Medtech organization ...
(Date:11/12/2019)... ... November 12, 2019 , ... G5, the leader in ... performance up to 25% and reduces cost-per-click by as much as 15%. An ... attribution (MTA) to predict best advertising outcomes and automatically allocate daily ad investments ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... , ... November 12, 2019 , ... ... services, welcomed their new Director of Forensic Genealogy, Melinde Lutz Byrne, to the ... (FGS) to ultimately provide investigative leads to law enforcement through proven genealogy ...
(Date:11/5/2019)... ... November 04, 2019 , ... Catalent, ... for drugs, biologics, gene therapies, and consumer health products, today announced the ... enhances Catalent’s proven GPEx expression platform through multiple improvements, including utilization of ...
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 graph, a breakthrough knowledge ... drug360 brings tellic’s expertise in biomedical language processing and machine learning to bear ... between genes, diseases, variants, phenotypes, and other biomedical entities. Researchers and analysts ...
(Date:10/29/2019)... , ... October 29, 2019 , ... ... of the skin*. Using Silios CMS-C multispectral imagers , researchers identified people ... can replace identification based on retinal imaging, face recognition, fingerprints and vasculature. ...
Breaking Biology Technology:
Cached News: